<DOC>
	<DOCNO>NCT00679211</DOCNO>
	<brief_summary>Study trastuzumab emtansine ( T-DM1 ) administer patient human epidermal growth factor receptor 2 ( HER2 ) -positive metastatic breast cancer .</brief_summary>
	<brief_title>A Study Trastuzumab-Mcc-DM1 Administered Intravenously Patients With HER2-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Signed studyspecific Informed Consent Form ( ) Age ≥ 18 year Histologically document breast cancer HER2positive disease Metastatic breast cancer Disease progression last chemotherapy regimen receive metastatic set Prior treatment anthracycline , trastuzumab , taxane , lapatinib , capecitabine neoadjuvant , adjuvant , locally advanced , metastatic set prior treatment least two line therapy ( line therapy combination two agent singleagent chemotherapy ) metastatic setting At least two line antiHER2 therapy must give metastatic set monotherapy combine chemotherapy hormonal therapy . The HER2targeted agent include trastuzumab , lapatinib , investigational agent HER2inhibitory activity . A minimum 6 week trastuzumab treatment metastatic disease require Patients must least 14 day exposure metastatic set lapatinib capecitabine ( give together separately ) unless intolerant lapatinib and/or capecitabine Chemotherapy ≤ 21 day enrollment Trastuzumab ≤ 21 day enrollment Hormone therapy ≤ 7 day enrollment Granulocytestimulating agent &lt; 14 day enrollment Investigational therapy ≤ 28 day enrollment Previous radiotherapy treatment metastatic breast cancer ≤ 21 day enrollment Brain metastasis untreated , symptomatic , require therapy control symptom ; radiation , surgery , therapy control symptom brain metastasis within 3 month first study treatment History intolerance ( include Grade 34 infusion reaction ) hypersensitivity trastuzumab murine protein History exposure follow cumulative dos anthracyclines : Doxorubicin liposomal doxorubicin &gt; 500 mg/m^2 ; Epirubicin &gt; 900 mg/m^2 ; Mitoxantrone &gt; 120 mg/m^2 idarubicin &gt; 90 mg/m^2 Peripheral neuropathy Grade ≥ 3 per National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) , v3.0 History malignancy within last 5 year , except carcinoma situ cervix basal cell carcinoma Current unstable angina History symptomatic congestive heart failure ( CHF ) , ventricular arrhythmia require treatment History myocardial infarction within 6 month enrollment Left ventricular ejection fraction ( LVEF ) &lt; 50 % within 28 day enrollment History decrease LVEF &lt; 50 % symptomatic CHF previous adjuvant trastuzumab treatment Severe dyspnea rest due complication advance malignancy require current continuous oxygen therapy Current severe , uncontrolled systemic disease ( e.g. , clinically significant cardiovascular , pulmonary , metabolic disease ) Major surgical procedure significant traumatic injury within 28 day enrollment anticipation need major surgery course study treatment Current pregnancy lactation Current know infection human immunodeficiency virus ( HIV ) , active hepatitis B , and/or hepatitis C virus Assessed investigator unable unwilling comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>MBC</keyword>
	<keyword>Trastuzumab emtansine</keyword>
</DOC>